We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adiponectin and Insulin Resistance in Diabetic Nephropathy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00774904
First Posted: October 17, 2008
Last Update Posted: October 20, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Shanghai Jiao Tong University School of Medicine
Information provided by:
Health Science Center of Xi’an Jiaotong University
  Purpose
Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).

Condition Intervention
Diabetic Nephropathy Drug: Losartan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan

Resource links provided by NLM:


Further study details as provided by Health Science Center of Xi’an Jiaotong University:

Primary Outcome Measures:
  • GFR, HbA1c and the adiponectin concentration [ Time Frame: 6 month ]

Enrollment: 80
Study Start Date: April 2007
Study Completion Date: November 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Losartan
    Angiotensin II Type 1 Receptor Blockers
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetic nephropathy
  • CKD at stage 1~4

Exclusion Criteria:

  • Type 1 diabetes or nondiabetic renal disease
  • An elevated plasma K level.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00774904


Locations
China
Shanghai No.3 people's hospital
Shanghai, China, 201900
Sponsors and Collaborators
Health Science Center of Xi’an Jiaotong University
Shanghai Jiao Tong University School of Medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: hui min Jin, shanghai No 3 people's hospital
ClinicalTrials.gov Identifier: NCT00774904     History of Changes
Other Study ID Numbers: ADPN
First Submitted: October 16, 2008
First Posted: October 17, 2008
Last Update Posted: October 20, 2008
Last Verified: October 2008

Keywords provided by Health Science Center of Xi’an Jiaotong University:
Type 2 Diabetes
Diabetic Nephropathy
Glucose Metabolism
Angiotensin II Type 1 Receptor Blockers

Additional relevant MeSH terms:
Insulin Resistance
Kidney Diseases
Diabetic Nephropathies
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Losartan
Angiotensin II Type 1 Receptor Blockers
Angiotensin II
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents